QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Accuray Inc. (ARAY) Granted 510(K) Clearance for Marketing New Feature of TomoTherapy System 0 comments
    Oct 25, 2011 5:52 PM | about stocks: ARAY

    Accuray Inc., the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions, today announced that the U.S. Food and Drug Administration has granted the company 510(k) clearance for the marketing of the Dose Control System (NYSE:DCS) for their TomoTherapy System in the United States. Accuray stated that the DCS feature allows for even higher precision in the dose stability throughout rotational treatments of image-guided radiation therapy in the TomoTherapy System by automatically adjusting controls to limit interruptions and ensuring steadiness over longer duration treatments. Customers can expect higher satisfaction, better patient experience and improved overall performance when the DCS feature is used.

    “FDA clearance of the new Dose Control System is a positive step toward improving TomoTherapy System performance and customer satisfaction,” said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray in a press release on Tuesday. “We are dedicated to offering our customers technological advancements that help streamline their workflow and expand the capabilities of their systems.”

    When the TomoTherapy system was introduced it revolutionized radiation therapy by providing the option to deliver slices of radiation precisely to target areas without harming surrounding healthy tissue. The advent of this new DCS feature will break new ground by providing an even higher precision of dose stability throughout complex rotational treatments. DCS feature automates what used to be a manual process thus allowing small variations to be immediately corrected which will be especially good for the long treatment procedures like Total Marrow and Total Body Irradiation.

    Accuray creates technologies that are used in 582 systems installed in hospitals worldwide that have treated over 200,000 patients. Their key technologies deliver radio surgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy.

    For more information on the Dose Control System or Accuray, please visit accuray.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
     

    Stocks: ARAY
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.